Last reviewed · How we verify
GSK1838262
At a glance
| Generic name | GSK1838262 |
|---|---|
| Also known as | XP13512 |
| Sponsor | XenoPort, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study (PHASE4)
- Simulated Driving Study in Restless Legs Syndrome (PHASE2)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment (PHASE2)
- XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. (PHASE3)
- Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome (PHASE2)
- XP13512 vs. Placebo in Patients With Restless Legs Syndrome. (PHASE3)
- A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) (PHASE2)
- A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1838262 CI brief — competitive landscape report
- GSK1838262 updates RSS · CI watch RSS
- XenoPort, Inc. portfolio CI